← Eichor
Condition: Nsclc Advanced Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nsclc Advanced Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Impact of Circadian Rhythm on Immunotherapy
Phase 2 · 1 location(s) · Liza Villaruz, MD · NCT07224971a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Phase 2 · 3 location(s) · Hackensack Meridian Health · NCT05715229Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · 770 location(s) · Mirati Therapeutics Inc. · NCT04613596A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Phase N/A · 3 location(s) · National Cancer Centre, Singapore · NCT06418412Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06554613A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/Phase 2 · 25 location(s) · Merck Sharp & Dohme LLC · NCT07286149Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: RO
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01639508A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Phase 1/Phase 2 · 14 location(s) · Krystal Biotech, Inc. · NCT06228326A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Phase N/A · 8 location(s) · Centre Leon Berard · NCT02511288Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Jian Chen · NCT06205927JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit
Phase 3 · 37 location(s) · Allist Pharmaceuticals, Inc. · NCT06416410A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With
EARLY_Phase 1 · 1 location(s) · People's Hospital of Quzhou · NCT07647094
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.